Last reviewed · How we verify

Nicotine Replacement Therapy Agent - Lozenges

NYU Langone Health · Phase 3 active Small molecule

Lozenges release nicotine into the bloodstream to help manage withdrawal symptoms and cravings.

Lozenges release nicotine into the bloodstream to help manage withdrawal symptoms and cravings. Used for Smoking cessation.

At a glance

Generic nameNicotine Replacement Therapy Agent - Lozenges
SponsorNYU Langone Health
Drug classNicotine replacement therapy
TargetNicotinic acetylcholine receptors
ModalitySmall molecule
Therapeutic areaAddiction
PhasePhase 3

Mechanism of action

Nicotine replacement therapy (NRT) works by replacing the nicotine that the body is used to getting from cigarettes. Lozenges are one type of NRT that dissolves in the mouth to release a controlled amount of nicotine into the bloodstream, helping to reduce withdrawal symptoms and cravings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: